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Background: Maternal immune activation and subsequent interleukin-6 (IL-6) induction disrupt normal brain
development and predispose the offspring to developing autism and schizophrenia. While several proteins have
been identified as having some link to these developmental disorders, their prevalence is still small and their
causative role, if any, is not well understood. However, understanding the metabolic consequences of environmental
predisposing factors could shed light on disorders such as autism and schizophrenia.
Methods: To gain a better understanding of the metabolic consequences of IL-6 exposure on developing central
nervous system (CNS) cells, we separately exposed developing neuron and astroglia cultures to IL-6 for 2 hours
while collecting effluent from our gravity-fed microfluidic chambers. By coupling microfluidic technologies to
ultra-performance liquid chromatography-ion mobility-mass spectrometry (UPLC-IM-MS), we were able to
characterize the metabolic response of these CNS cells to a narrow window of IL-6 exposure.
Results: Our results revealed that 1) the use of this technology, due to its superb media volume:cell volume ratio,
is ideally suited for analysis of cell-type-specific exometabolome signatures; 2) developing neurons have low
secretory activity at baseline, while astroglia show strong metabolic activity; 3) both neurons and astroglia respond
to IL-6 exposure in a cell type-specific fashion; 4) the astroglial response to IL-6 stimulation is predominantly
characterized by increased levels of metabolites, while neurons mostly depress their metabolic activity; and 5)
disturbances in glycerophospholipid metabolism and tryptophan/kynurenine metabolite secretion are two
putative mechanisms by which IL-6 affects the developing nervous system.
Conclusions: Our findings are potentially critical for understanding the mechanism by which IL-6 disrupts brain
function, and they provide information about the molecular cascade that links maternal immune activation to
developmental brain disorders.
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Maternal immune activation (MIA) strongly contributes
to the pathophysiology of multiple brain disorders in the
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not merely a reaction to a primary disease process, but an
etiological contributor to the disease itself [6,7]. It has
been well documented that disturbed cytokine levels can
cause long-term behavioral changes. For example, in
animal models, maternal infection with influenza virus
during pregnancy leads to long-lasting microanatomical,
neurochemical, and behavioral changes in the brains of
the offspring [8,9]. However, such changes are not medi-
ated directly by the viral infection [10]. Rather, MIA ap-
pears to be the key [11], as offspring of mothers exposed
to polyinosinic:polycytidylic acid (polyI:C, a syntheticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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to those of offspring whose mothers were exposed to virus
infection [12].
MIA triggers a complex immune response that ultim-
ately alters the developmental trajectory of the fetal brain
[9]. Cytokines play a critical role in MIA, and in particular,
interleukin-6 (IL-6) induction appears to be responsible
for many of the long-lasting behavioral changes seen in
MIA-born offspring [13,14]. IL-6, a pro-inflammatory
cytokine with a profound effect on brain function [15,16],
is elevated as a result of various MIA paradigms, and ex-
posure to IL-6 gives rise to a similar behavioral phenotype
that is observed in offspring of mothers exposed to flu,
lipopolysaccharide (LPS), or polyI:C [12-14]. Furthermore,
blocking IL-6 effects with anti-IL-6 antibody during
influenza-virus infection, polyI:C exposure, or IL-6 chal-
lenge prevents the deleterious effects of MIA [13], thus
suggesting that the IL-6 inflammatory cascade is a critical
(and at least partially causal) mediator of the deleterious
effects observed in the offspring.
Within the central nervous system, cells communicate
through multiple mechanisms, including synaptic contacts,
active secretion of proteins, and release of metabolites. The
non-synaptic communication between the various brain
cell types is extremely important during development, and
the various chemical gradients are critical for brain pat-
terning, neuronal differentiation and migration, laminar
development and establishment of the synaptic framework
[17]. Thus, the ability to study the molecular secretions in
the developing brain in a high-throughput, unbiased way
provides insight into typical fetal brain development and
pathological processes that result in developmental disor-
ders. Custom-made, microfabricated bioreactors (such as
microfluidic chambers) offer the opportunity to maintain
tissue explants and small numbers of primary cells in a
close-to-physiological environment, wherein the extracellu-
lar volume and fluid interconnectivity between cellular
compartments are sufficiently optimized for studying
paracrine and autocrine signaling phenomena without
dilution [18,19]. This, coupled with ultra-performance
liquid chromatography - ion mobility - mass spectrom-
etry (UPLC-IM-MS), provides an opportunity to study
the exometabolomic features of numerous cell types
under tightly controlled conditions [20] and with nar-
row temporal resolution.
Considering these strengths, we have applied micro-
fluidic-based culturing of embryonic neurons and glial
cells to study their exometabolomic activity under resting
conditions and upon stimulation with interleukin-6. In a
comprehensive comparison of baseline and IL-6-induced
changes across these two cell types, we putatively identi-
fied metabolites and molecular pathways that might play a
critical role in the pathophysiology of neurodevelopmental
disorders.Methods
Experimental animals
C57 black male and female mice were kept in mating for
3 days. E0 was defined as time of vaginal plug. At E15
pregnant females were euthanized with isofuran over-
dose and embryos removed. The ventral midbrain was
isolated as previously described [21]. All procedures
were in accordance with IACUC standards and were
approved by Vanderbilt’s Institutional Animal Care and
Use Committee for use in this study.
Neuronal and astroglial cell cultures
Neuronal cultures were prepared as previously de-
scribed using Hibernate-E dissection media [22]. The
ventral midbrain of each E15 embryo was dissociated in
Hank’s balanced salt solution (HBSS) containing 1% pa-
pain and 5 U mL−1 DNase (Worthington Biochemicals,
Lakewood, NJ, USA) and transferred to a solution con-
taining 1% ovomucoid protease inhibitor (Worthington
Biochemicals, Lakewood, NJ, USA). After dissociation,
neurons and astroglia were separated by magnetic cell
sorting using established protocols [23]. Dissociated
cells were immuno-enriched using a PNCAM antibody
(Miltenyi Biotec, Bergisch Gladbach, Germany), thus
positively selecting for neurons and allowing astroglia to
be collected in the flow-through. This purification
method achieved approximately 94% purity in cell culture.
Following centrifugation, purified neurons were resus-
pended in neural basal (NB) culture media (supplemented
with B-27 and 2 mM L-glutamine) and loaded into poly-
D-lysine (10 μg ml−1) and laminin (9.6 μg ml−1)-coated
microfluidic chambers. Primary astrocyte cultures were
reconstituted and maintained in minimum essential
medium (MEM) (supplemented with 10% albumin and
N-2) for 3 days. On day 4, cell culture media was ex-
changed for NB culture media (supplemented with B-27
and 2 mM L-glutamine) for the following 3 days [24-26].
Microfluidic chambers were loaded with approximately
200,000 cells/well and cell cultures were maintained at a
constant gravity-fed flow for 6 days prior to exposure.
Exposure to IL-6
On the 6th day, the above-described culturing media
was replaced with media containing 100 ng ml−1 IL-6
(Shenandoah Biotech, Warwick, PA, USA) for 2 hours.
Following media replacement, effluent was collected for
2 hours, collecting a total flow-through volume of
60 μl/sample. Three biological replicates for each condi-
tion were collected. (Experimental conditions: Neuronal
cultures, Neuronal cultures + IL-6, Astroglial cultures,
Astroglial cultures + IL-6; Controls: Empty microfluidic
chamber containing no cells, Empty microfluidic cham-
ber no cells + IL-6). Each UPLC-IM-MS measurement
was performed in triplicate (technical replicates).
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Microfluidic devices were fabricated using standard soft
lithography methods [27,28] as previously described
[29-31]. First, a master mold was formed using a negative
SU-8 photoresist. Spin-coating SU-8 2100 (Microchem,
Newton, MA, USA) on a silicon wafer at 1500 RPM re-
sulted in a uniform layer of photoresist approximately
200-μm thick. Standard photolithographic methods were
used to pattern the desired microchannel features into
the SU-8. Briefly, the SU-8 film was exposed to UV
light through a 20,000 DPI printed transparency mask
(CAD-Art, Bandon, OR, USA), baked for 2 hours at
95°C, and processed with SU-8 developer to yield a 3D
relief of the 2D pattern on the mask. After fabrication
of the mold, liquid polydimethylsiloxane (PDMS) pre-
polymer (Dow Corning, Midland, MI, USA) was mixed
with its curing agent (10:1 ratio) and poured over the
mold. The PDMS was then degassed for approximately
1 hour and cured in a 70°C oven for at least 2 hours.
Following curing, the PDMS layer was removed from
the SU-8 mold, and 5-mm diameter holes were punched
in the inlet and outlet of each microfluidic channel. Air
plasma bonding was then used to attach the PDMS layer
to a glass cover slip (VWR Vista Vision, Suwanee, GA,
USA). After bonding, Pyrex cloning cylinders (Fisher Sci-
entific, Pittsburgh, PA, USA) were adhered to the inlet/
outlet regions of each channel to form small reservoirs
to load and remove cells and culture media. Prior toFigure 1 Experimental design and analysis strategy. (A) Microfluidic de
prior to IL-6 exposure. (B) Illustration of the sample preparation method fo
neurons ± IL-6). Samples were prepared for exometabolomic analyses and an
mobility-mass spectrometer.use, individual microfluidic channels were stored in de-
ionized water.
Microfluidic devices consisted of four separate micro-
channels, each having an inlet and outlet channel and
one cell culture chamber region (Figure 1A). The devices
were designed to reduce flow velocity by expanding the
cell culture chamber. The larger cell culture chamber,
with dimensions of 5,400 μm (length) × 800 μm (width) ×
200 μm (height), facilitates cell attachment and has a
total volume of approximately 0.86 μL. A PDMS wall
separates the four chambers, ensuring that no cross talk
occurs among cell culture regions.
Sample preparation for mass spectrometry
Metabolites were prepared for ion mobility - mass spec-
trometry (IM-MS) analysis by concentrating in vacuo
(SpeedVac concentrator, Thermo-Fisher) and reconstitut-
ing in 60 μL of 90% acetonitrile, 10% H2O, and 20 mM
ammonium acetate (pH = 9). Quality control samples
were prepared by combining equal volumes (15 μL) of
each sample type.
Mass spectrometry and data analyses
UPLC-IM-MS and data-independent acquisition (MSE)
were performed on a Waters Synapt G2 HDMS (Milford,
MA, USA) mass spectrometer equipped with a Waters
nanoAcquity UPLC system and autosampler (Milford, MA,
USA). Metabolites were separated on a 1 mm× 100 mmvices or bioreactors were seeded with neurons or astroglia for 6 days
r bioreactor perfusate samples (control ± IL-6, astroglia ± IL-6, and
alysis performed using an ultra-performance liquid chromatography-ion
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ethylene bridged hybrid (BEH) particles (Waters, Milford,
MA, USA). Liquid chromatography was performed using a
20-minute gradient at a flow rate of 90 μL min−1 using solv-
ent A (10% H2O (v/v) with 10 mM ammonium acetate at
pH 9 in acetonitrile) and solvent B (100% H2O with
10 mM ammonium acetate at pH 9). A 3-min wash
period (99% solvent A) was performed prior to any gra-
dient changes. After 3 min, solvent B increased to 75%
over 12.5 min and up to 50% in 15 min. The column
was re-equilibrated to 99% solvent A for 5 min after
each run. Typical IM-MS analyses were run using reso-
lution mode, with a capillary voltage of 3.5 kV, source
temperature at 120°C, sample cone at 5, source gas flow
of 400 mL min−1, desolvation temperature at 400°C, He
cell flow of 180 mL min−1, and an IM gas flow of
90 mL min−1. The data were acquired in positive ion
mode from 50 to 1700 Da with a 0.3 s scan time; full-
scan data were mass corrected during acquisition using
an external reference consisting of 3 ng mL−1 solution of
leucine enkephalin infused at a flow rate of 7 μL min−1.
All analytes were analyzed using MSE with an energy
ramp from 10 to 45 eV.
Data analysis
The integrated intensity of each chromatographically re-
solved m/z peak was log2 transformed. Differences in
these peak areas were determined using the average
logarithmic ratio (ALR =meanEXP - meanCNTR). Statistical
significance was determined using unpaired two-tailed
Student’s t-test. Both biological and technical replicates
were used in these calculations. An m/z species was con-
sidered differentially expressed when it met the dual
criteria of absolute value |ALR| >0.585 (50% change)
and P value <0.05. Direction of change was defined as
ALRs >0.585 = produced ALRs < -0.585 = consumed. The
log2 peak area values of species with differential levels be-
tween the experimental and control samples were sub-
jected to a two-way unsupervised hierarchical clustering
analysis based on Euclidian distance using GenePattern
software [32].
Identification of analytes by ion mobility - mass
spectrometry
The raw data acquired were converted to mzXML files
using ProteoWizard msconvert [33]. Following conver-
sion, mzXML files were analyzed using XCMS in the
statistical package R Studio (v 0.97.449) to pick and align
features (that is, retention time (RT) - mass-to-charge
(m/z) ratio pairs). XCMS was used with default settings
except for rector (method = ‘obiwarp’). Data were then
normalized to the summed total ion intensity per chro-
matogram, with the total ion count normalized to 10,000
counts. The resulting processed data matrix was introducedinto uMetrix (Version 2.0.0) EZ Info multivariate statistical
analysis software for principal component analysis (PCA)
with Pareto scaling.
Metabolite peak identifications were putatively assigned
using both accurate mass measurements and MS/MS ana-
lysis. Ion mobility separations were utilized to isolate pre-
cursor ions, correlate product ions, and discern in-source
fragmentation. Candidate structures were obtained and
interpreted with available biochemical databases, including
METLIN [34], the Human Metabolome Database [35], and
LIPID MAPS [36] [see Additional files 1, 2, 3, 4 and 5].
Determination of metabolomics differences
Principal component analysis was performed on expression
levels of all measurable analytes using uMetrix (v 2.0.0) EZ
Info extended statistics software. Unsupervised, two-way
hierarchical clustering (samples versus analytes) was per-
formed on normalized log2 analyte levels in GenePattern
[32] using Pearson distance. To determine differentially
expressed analytes, all analyses were performed on log2-
transformed values. Analytes were considered differentially
expressed if they met a dual set of criteria of magnitude
change and significance (P <0.05; │ALR│ >0.585). Add-
itionally, for an analyte to be changed under IL-6 stimula-
tion, it also had to be significantly different (P <0.05) from
the IL-6 media perfused through the microfluidic chamber
containing no cells. These calculations were performed in
MS-Excel 2010.
Results
Resting astroglia and neurons exhibit distinct metabolic
signatures
To investigate the resting-state metabolic signatures of
astroglia and neurons, these cells were isolated from E15
mouse embryos using magnetic beads and cultured for
6 days in microfluidic chambers (Figure 1A). On day 6,
we collected conditioned media from neuronal and astro-
glial cells, and as a control, media was perfused through
the microfluidic device that contained no cells. Each con-
ditioned media was prepared and analyzed by UPLC-IM-
MS (Figure 1B). Following data processing (peak picking
and alignment), 2,295 unique features (with each feature
having both a mass-to-charge ratio (m/z) and a retention
time (RT)) were detected [see Additional file 6: Dataset 1].
To enable study of the metabolic signatures and differ-
ences between cell types, the area of each UPLC-IM-MS
peak from media for each cell type (neurons and astroglia)
was compared to the same features in control media
using a paired t-test. In this analysis, 14% (327) of the
detectable exometabolites reported significantly different
levels (P <0.05) between neuronal cultures and control
conditions. In contrast, 99% (2,278) of the detectable exo-
metabolites were present at significantly different levels
(P <0.05) between astroglia and matched controls.
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1,576 (69%) were at lower levels in astrocyte-conditioned
media than in the control media (three downward arrows
in the astrocyte circle in Figure 2A), consistent with the
astroglia metabolizing the associated chemical species
provided by the original media. For the astroglial media,
increased levels of 702 features (31%) relative to the con-
trol are indicated by upward arrows and represent produc-
tion of these species by the astroglia. In contrast, neurons
consumed 62 (19%) and produced 265 (81%) species.
However, it is noteworthy that the exometabolic activ-
ity observed in neurons showed a large overlap with the
species observed in astroglia: of the 327 species con-
sumed or produced by neurons, 310 (94.8%) were com-
mon to both the astroglial and neuronal media, with
289 (93.2%) of these showing the same directionality of
changes (Figure 2A). We hypothesize that this common
neuronal-astroglial exometabolic signature reflects basic
homeostatic activity such as glucose utilization, mito-
chondrial function, and basic protein/lipid turnover.
Next, to directly compare the levels of astroglial species
with the neuronal ones, we used a combined paired t-test
and magnitude-change criteria applied to the average log2
ratio (ALR), such that P <0.05 AND│ALR│ >0.585, whichFigure 2 Unstimulated neurons and astrocytes have a distinct exome
features with significant differences between neurons versus control, and a
analytes reporting significantly different levels, while arrows denote directio
containing no cells). Note that the astrocytes show much higher metabolic
metabolites are also observed in cultured astrocytes. Of the 2,278 species
as compared to 19% in the neuronal media. (B) Clustering of unstimulate
two-way unsupervised hierarchical clustering analysis of normalized meta
their unstimulated state after subtraction of the peak areas for control me
biological and technical replicates (for example, A1R1 - astroglia biologica
species identified by the ultra-performance liquid chromatography - ion m
denotes higher metabolite production in comparison to the other cell typ
feature of the astrocytic cultures, and that the clustering separated the bio
astroglial clusters.selects only species with a >50% difference. Of the original
2,278 species, 872 species met both criteria and revealed
that astroglia produced approximately 15× more metab-
olites than neurons (astroglia = 824, neurons = 48) [see
Additional file 7: Dataset 2].
For all technical and biological replicates and each of
the 872 species, we computed the deviation of the astro-
glial and neuronal levels of each sample from the com-
bined mean of that species for all samples. This created
a matrix of 872 × 18. We then performed a two-way un-
supervised hierarchical clustering on this matrix to pro-
duce the self-organized data in Figure 2B. The deviation
from the mean was color-coded (red > mean, blue <
mean), with the intensity of each color proportional to
the magnitude of that deviation. This analysis demon-
strates the technical and biological reproducibility of
the measurements of these 872 species, and that the
unsupervised clustering separates the species by the
cell type that conditioned the media. Hence, our data
suggest that astroglia and neurons have distinct meta-
bolic signatures under resting conditions, while astro-
glia have a robust consumption/production metabolic
activity and neurons consume/produce fewer metabo-
lites in their resting state.tabolomic profile. (A) Venn diagram illustrating the number of
strocytes versus control (P <0.05). Numerals denote the number of
nality of change in comparison to controls (perfused chambers
activity than neurons, and that 94.8% of the changed neuronal
detected in the astrocyte-conditioned media, 69% were consumed,
d astrocytic and neuronal exometabolomic profiles. Heat map shows
bolomics data for the features observed in astrocytes and neurons in
dia (for analytes, [see Additional files 6, 7, 8 and 9]). Columns represent
l replicate 1 technical replicate 1), rows represent individual chemical
obility - mass spectrometry (UPLC-IM-MS). In individual features, red
e. Note that higher metabolite production was the predominant
logical and technical replicates into two distinct neuronal and
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to IL-6 challenge
To investigate the metabolic response of each cell type
to pro-inflammatory cytokine stimulation, we cultured
the isolated astroglia and neurons in microfluidic de-
vices, and cultures were exposed to 100 ng ml−1 IL-6 for
2 hours on day 6. Control cells were exposed to vehicle
only, and the control device contained no cells but was
perfused with media containing IL-6. To address the issue
of toxicity for both IL-6 dose and exposure time, neuronal
and glial cells ± IL-6 were imaged 1 hour after treatment
using β3-tubulin antibody (TUJ-1, a neuronal marker) or
glial fibrillary acidic protein (GFAP, astrocyte marker)
staining. Assessments did not reveal any change in process
length, cell density, or other morphological signs of tox-
icity (Figure 3A).
The extracellular metabolomic signatures of neuronal
and astroglial samples were significantly altered in re-
sponse to IL-6 stimulation [see Additional files 8 and 9].
In the neuronal cultures, we observed 27 metabolites that
changed in response to IL-6 exposure, with nine features
exhibiting increased abundances and 15 demonstrating
decreased abundances [see Additional files 8 and 9]. The
response of the astroglial cultures to IL-6 exposure was
more pronounced; of the 45 changed species, 28 species
reported increased exometabolomic abundances, while 17
species were observed at reduced levels in the media [see
Additional files 8 and 9]. Importantly, the responses of
neuronal and astroglial cultures to IL-6 stimulation were
quite distinct (Figure 3B): the observed neuronal changes
were dominated by exometabolome decreases, while the
majority of the astroglial alterations were increases. It is
also noteworthy that three secreted species were signifi-
cantly different in both the neurons and astroglia when
compared to non-IL-6 exposed cultures (m/z 664.291,
RT = 232 s; m/z = 760.278, RT = 213 s; m/z 748.234,
RT = 109 s), with all showing opposite directionality of
change between the two cell types [see Additional files 8
and 9]. These data illustrate that the initial, narrow time
window for metabolic response of astroglia to IL-6 stimu-
lation was predominantly characterized by an increase in
metabolite production, while neurons increased their me-
tabolite consumption.
These data comparisons between neuronal cultures,
astroglial cultures, and control conditions demonstrate
the powerful capabilities of UPLC-IM-MS analysis with-
out a priori knowledge. This is also demonstrated by a
principal component analysis (PCA) that distills multi-
dimensional data sets (in these data, approximately
2,300 m/z-RT pairs) to principal components that best
describe the greatest covariance in the data, thus pro-
viding sample grouping or separation based on patterns
in the data. Global PCA of processed UPLC-IM-MS data
from neurons, astroglia, and controls further confirmedthat the global metabolic signatures between neuronal and
glial sample types were quite distinct (Figure 3C).
Identification of selected analytes by ion mobility - mass
spectrometry
Peak identifications were performed using accurate
mass and ion adduct information for database searching
(METLIN [34], LIPID MAPS [36], and the Human
Metabolome Database [35]) to produce candidate struc-
tures. Candidate structures were then validated using
retention time and ion mobility-filtered high-energy
data. Fragmentation is performed after the mobility sep-
aration, and therefore, product ions retain the mobility
of the precursor. This allows untargeted fragmentation of
all ions to be filtered into relevant high-energy spectra.
From the prioritized list of metabolites altered by
IL-6 exposure, we putatively identified three analytes
(Figure 4A) that belong to the glycerophospholipid
metabolism pathway (Figure 4B). The connection of this
pathway to brain IL-6 activation has not previously
been described. N-methylethanolamine phosphate was
observed to be increased in the IL-6-exposed neurons
(m/z = 156.065, RT = 314 s, ALR = 1.81, P <0.001) in
comparison to the sham-treated neuronal cultures.
Baseline levels of N-methylethanolamine phosphate
were significantly higher in the glial cultures compared
to those observed in the neuronal cultures. N-methy-
lethanolamine phosphate can be produced through the
transfer of a methyl group from S-adenosyl methionine
to phophoethanolamine, catalyzed by phosphoethanola-
mine methyltransferase. This metabolite has an import-
ant biological role in glycerophospholipid metabolism
and in development [37]. Importantly, the production of
at least two other glycerophospholipid metabolites was
detected in the secreted metabolome of IL-6 stimulated
astroglia: diacylglycerophosphocholine (m/z = 732.551,
RT = 216 s, ALR = 1.57, P <0.001) and diacylglyceropho-
spho-ethanolamine (m/z = 768.564, RT = 124 s, ALR =
1.39, P <0.001). Glycerophosphocholines are the inactive
form of long-chain polyunsaturated fatty acids (LCPUFAs),
arachidonic acid (AA), docosahexaenoic acid (DHA), and
eicosapentaenoic acid (EPA), and the disturbed metabolism
of these species has been previously linked to schizophre-
nia, major depression, and bipolar disorder [38-42].
In addition, in both neuronal and astroglial cultures
we observed IL-6-induced exometabolome changes in
the tryptophan-kynurenine pathway, a pathway strongly
modulated by IL-6 activity in the brain. Kynurenine
(m/z = 209.10, RT = 78 s) was observed to decrease in
astroglial cultures in response to IL-6 exposure (Figure 5A,
ALR = −0.86, P <0.00001), whereas formylanthranilate
(m/z = 166.07, RT =70 s) was observed to increase in
neuronal cultures in response to IL-6 exposure (Figure 5B,
ALR = 2.47, P <0.001). Formylanthranilate is a
Figure 3 Effects of IL-6 exposure on astrocytes and neuronal cultures. (A) Cultured neurons and astrocytes were exposed to IL-6 for 2 hours
and allowed to recover for 1 hour prior to imaging. Cells were fixed with 4% PFA and labeled with neuronal marker Tuj-1 or GFAP, an astrocyte
marker. Appearance, process length, and cell density were similar to the untreated, matched controls. (B) Venn diagram illustrating the number of
features with significant differences between IL-6 treatment and matched, sham-treated control cultures (P <0.05;│ALR│>0.585, that is, >50% of
control). Numerals denote the number of features (m/z and retention time pairs) with significantly different levels, while arrows denote directionality of
change in comparison to controls. Note that the neuronal and astroglial exometabolome response to IL-6 treatment is distinct. (C) Global principal
component analysis (PCA) of ultra-performance liquid chromatography - ion mobility - mass spectrometry (UPLC-IM-MS) data illustrating that there are
distinct metabolic signatures between neuronal and astroglial sample types.
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Figure 4 Activation of glycerophospholipid metabolism in response to IL-6. (A) Numerous glycerophospholipid metabolites were significantly
produced upon IL-6 exposure in both astrocytes and neuronal cultures. Three analytes were putatively identified as diacylglycerophosphocholine (m/z
732.55, ALR = 1.57, P <0.001), diacylglycerophospho-ethanolamine (m/z 768.56, ALR = 1.39, P <0.001), and n-methylethanolamine (m/z 156.04, ALR =
1.81, P <0 .001). Putative identifications were obtained by using mass measurement accuracy, retention time and confirmed based on fragmentation
spectra [see Additional files 1, 2, 3, 4 and 5]. (B) Illustrates a simplified glycerophospholipid metabolism pathway and shows that n-methylethanolamine is
a precursor metabolite to numerous developmentally important downstream metabolites.
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yields neuroactive intermediates and has implications in
the modulation of neurotransmitter systems [43]. Im-
portantly, both formylanthranilate and kynurenine are
part of the tryptophan-kynurenine metabolic pathway,
and disturbances of this pathway are considered com-
mon mediators of genetic and environmental effects in
major depressive disorder [44] and appear to contribute
to schizophrenia pathophysiology [41,45]. Taken to-
gether, these data suggest that glycerophospholipidFigure 5 Alterations to the kynurenine pathway after IL-6 treatment.
(kynurenine) and (B) m/z 166.05 (formylanthranilate). Spectra were mobility
(A) In astrocyte cultures, we observed a decrease in normalized ion signal
209.10). (B) In contrast, we observed an increase in ion signal for formylant
when neuronal cultures were treated with IL-6, ALR = 2.47, P <0.001. Taken
astrocytes but does so in an opposite manner.metabolism and tryptophan-kynurenine metabolite secre-
tions are important (and potentially related) metabolic
pathways by which IL-6 inflammation affects the develop-
ing nervous system and predisposes it to developing a
brain disease.
Discussion
In traditional culture systems, cells are grown in a vol-
ume of media that is large enough to require media
changes no more than once per day [46], often dilutingHigh energy (fragmentation) mass spectra for (A) m/z 209.10
separated to isolate only product ions for 209 and 166, respectively.
after IL-6 treatment, ALR = −0.86, P <0.00001, for kynurenine (m/z
hranilate (m/z 166.05), also a component of the kynurenine pathway,
together, these data show that IL-6 exposure alters both neurons and
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Molecular signals can ostensibly be concentrated by pro-
longed culturing time, but at a cost of significant loss in
temporal resolution. This is problematic, since cellular
response to cytokine exposure is swift [49] and typical
physiological effects of cytokines are characterized by
rapid cycles [50]. To address these issues, we imple-
mented a microfluidic culture chamber system with a
30-fold decrease in metabolite dilution when compared
to conventional culture methods. This provided a means
to increase temporal sampling resolution of the exome-
tabolome, thereby utilizing the resultant increase in the
sensitivity to changes in the concentrations of extracellular
secretion. This increased sampling rate decreased the
probability of analyte degradation and dilution over time.
Furthermore, in the future it will allow investigators to
perform continuous post-stimulation sampling in narrow
time windows, opening the door to reconstruction of
temporal cascades of metabolic activity.
Astroglia are well known to communicate with secreted
molecules, and astrocyte-conditioned media has proven
beneficial for neuronal growth and survival [47]. Thus, it
is not surprising that astroglial cultures at baseline pro-
duce almost ten times more detectable analytes than neur-
onal cultures. An unexpected finding, however, was that
resting astrocytes depleted the media of 1,576 analytes, or
69% of detected compounds. Identification of these con-
sumed compounds and understanding the process of re-
source utilization will be important topics for future
studies. It is also important to note that while the neurons
enriched the conditioned media by only 15 detected ana-
lytes, we cannot exclude the possibility that these mole-
cules are critical for neuronal-neuronal, neuronal-glial, or
neuronal-microvascular communications [51].
The outcome of the IL-6 stimulation was perhaps the
most interesting finding in our dataset. Neuronal and
glial response to IL-6 stimulation was quite distinct,
non-overlapping, and divergent: astroglia predominantly
increased their metabolite production, while neurons
primarily consumed resources from the media. We be-
lieve that these two metabolic signatures are parts of an
essential chemical communication mechanism between
neurons and glia under stress, and they perhaps repre-
sent an initial neuroprotective response to adverse
conditions. In follow-up experiments, we were able to
positively identify five distinct metabolites that were de-
creased in astroglia-conditioned media in response to
IL-6 stimulation. These included diacylglycerophos-
phocholine, diacylglycerophospho-ethanolamine, and l-
kynurenine, whereas N-methylethanolamine phosphate
and formylanthranilate secretion increased in IL-6-
stimulated neuronal cultures.
Diacylglycerophosphocholine and diacylglycerophospho-
ethanolamine belong to the class of glycerophospholipids(GPLs), an inactive pool from which bioactive lipids are
synthesized [52,53]. Neuronal-astroglial membranes con-
tain several classes of GPLs, which constitute the mem-
brane backbone and define membrane properties such as
fluidity and ion permeability [52,54]. GPLs and the com-
plementary bioactive lipid breakdown products have been
shown to modulate membrane excitability, monoaminergic
neurotransmission, and brain development [39,55]. Recent
evidence suggests that GPL metabolism is a critical dis-
turbance across multiple brain diseases, as degradation of
GPLs by phospholipase A2 can release arachidonic acid
and docosahexaenoic acid. The subsequent peroxidation
and enzymatic processing of these long-chain polyunsatur-
ated fatty acids produces multiple bioactive lipid mediators,
all closely associated with neuronal metabolic pathways
involved in the pathophysiology of major depression,
schizophrenia, and Alzheimer’s disease [56-58]. Further-
more, plasma phospholipid concentrations have been
demonstrated as predictive of memory impairment in
elderly adults [59].
In addition to altered GPL metabolism, exposure to IL-6
demonstrates a significant effect on at least two metabolites
within the tryptophan-kynurenine pathway. L-kynurenine
is the metabolite whose breakdown leads to the generation
of bioactive kynurenic and quinolinic acids, which act
on the glutamatergic and nicotinic neurotransmission
as antagonists and agonists, respectively [60-62]. The
tryptophan-kynurenine pathway is intricately linked to
inflammatory cytokines through the enzyme of indolea-
mine 2,3-dioxygenase (IDO), which is the rate limiting
step in the degradation of tryptophan into kynurenine
and the subsequent formation of downstream metabo-
lites [63,64]. Tryptophan metabolites demonstrate im-
munomodulatory effects, with increased tryptophan
metabolites leading to apoptosis and cell cycle arrest
and induction of T regulatory cells [65,66]. Neuroimag-
ing, biomarker, and animal model studies all indicate
that disturbances in the tryptophan-kynurenine pathway
are a critical pathophysiological event in major depression
[38,64,67] and potentially other neuropsychiatric disorders
[41,62,68,69]. Our observation of altered kynurenic acid
and formylanthranilate levels (both critical components of
the tryptophan-kynurenine pathway) in response to IL-6
stimulation suggests that our system is relevant for study-
ing brain disease-related processes and allows future
dissection of this molecular pathway under controlled
stimulation of astrocytes and neurons. Furthermore, our
experimental system has the capability to dissect the
secretory interplay between different brain cell types and
immune cells, including (but not limited to) astroglia, neu-
rons, microglia, and ependymal, endothelial, and T cells,
as well as the study of the blood-brain barrier [70].
Based on our results, we hypothesize that the previ-
ously described detrimental effects of IL-6 on developing
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astroglia to IL-6, resulting in an altered exometabolomic
profile, which in turn has a damaging effect on neurons.
We intend to investigate this hypothesis further in follow-
up, mechanistic studies which would test the effects the
IL-6-induced astroglial exometabolome has on neuronal
differentiation, growth, and synapse formation. This inves-
tigation, coupled with precise identification and testing
the effects of individual metabolites, would lead to a better
understanding of neurotoxic and neuroprotective pro-
cesses that might occur in the developing brain. Future
experiments will also encompass defining exometabolo-
mic changes, responses, and interplay between various
subclasses of neurons and across the various brain re-
gions, leading to three-dimensional in vitro modeling of
the brain.
It is also noteworthy that IL-6 response is quite con-
served across species [71-73] and that the general CNS
development in rodents is governed by the same basic
principles as in humans [74]. Thus, we believe that our
findings, obtained on developing mouse neurons, are also
relevant for human conditions such as schizophrenia and
autism. This view is also underscored by human disease
findings of elevated cytokines in schizophrenia and autism
[6,7,10], as well as the critical role of IL-6 in maternal im-
mune activation models [8-10].
Conclusions
In summary, our studies utilize microfluidic technology
with a superb cell-to-media volume ratio, which is ideally
suited for analysis of cell-type-specific metabolic signa-
tures. We find that 1) developing neurons have lower
metabolic activity at baseline than astroglia, which show
strong production of metabolites; 2) both neurons and
astroglia respond to IL-6 exposure in a cell-type-specific
fashion; 3) with IL-6 stimulation of each cell type, metabol-
ite production predominantly increases for the astrocytes
as compared to sham-treated cells, but decreases for neu-
rons; and 4) disturbances in glycerophospholipid metabol-
ism and tryptophan/kynurenine metabolite secretion are
two important mechanisms by which IL-6 might affect the
developing nervous system.
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